Mohamed El Idrissi - Concepedia

Author

Mohamed El Idrissi

Also Known As

M El Idrissi, M Idrissi, M. El Idrissi, M. El Ouali Idrissi, M. Idrissi, MAJDA IDRISSI, Mohamed El Idrissi, Mohamed Idrissi, Mohammed Bouziani Idrissi

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (United States)CureVac (Germany)Duke Medical Center Dalhousie University

About

Mohamed El Idrissi is an author at GlaxoSmithKline (Belgium) specializing in vaccinology, vaccine safety, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	403
2	Immunology	1	1	242
3	Clinical Trials	1	1	242
4	Immunotherapy	1	1	242
5	Precision Vaccinology	1	1	242

Mohamed El Idrissi

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi, JAMA	2019	244
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis Alemnew F. Dagnew, Osman İlhan, Won Sik Lee, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyVaccine DevelopmentMedicine	2019	242
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study Elchonon M. Berkowitz, Graeme Moyle, Hans‐Jürgen Stellbrink, The Journal of Infectious Diseases	2014	208
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial Peter Vink, Josep Ramón, Ana Sánchez‐Fructuoso, Clinical Infectious Diseases	2019	185
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients Edward A. Stadtmauer, Keith M. Sullivan, Francisco M. Marty, Blood	2014	177
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial Janet E. McElhaney, Jeanne‐Marie Devaster, Meral Esen, The Lancet Infectious Diseases VaccinationVaccine SafetyCross-protectionVaccinologyElderly People	2013	161
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial Peter Vink, Ignacio Delgado Mingorance, C. Maximiano Alonso, Cancer	2019	112
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials Marta López‐Fauqued, Laura Cámpora, Frédérique Delannois, Vaccine	2019	61
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants Sonia Budroni, Francesca Buricchi, Andrea Cavallone, npj Vaccines	2021	58
Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older Robert B. Couch, José M. Bayas, Covadonga Caso, BMC Infectious Diseases	2014	41

Page 1